Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials

The results of our third trial on epicutaneous allergen-specific immunotherapy (EPIT) will be presented and discussed in the context of our previous trials. This monocentric, placebo-controlled, double-blind phase I/IIa trial included 98 patients with grass pollen rhinoconjunctivitis. Prior to the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Senti, G, von Moos, S, Tay, F, Graf, N, Johansen, P, Kündig, T M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654258/
https://www.ncbi.nlm.nih.gov/pubmed/25704072
http://dx.doi.org/10.1111/all.12600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654258/
https://www.ncbi.nlm.nih.gov/pubmed/25704072
http://dx.doi.org/10.1111/all.12600

Ejemplares similares